Boehringer Ingelheim
For Healthcare Professionals

Document ID: PC-MY-102059

Speaker: Dr Cheah Soon Keat

Uncovering the Uncommon: Efficacy of Afatinib in Uncommon and Compound Mutations

Watch Dr Cheah Soon Keat as he discusses on the latest treatment strategy of treating uncommon EGFR mutation positive NSCLC patients based on evidence and clinical experience.

Expert Conversations

Malaysia Region Tumour Heterogeneity in Lung Cancer Asian setting
MYEEE||EGFR TKI-related Dermatological Adverse Events
MYEEE||Evidence for Sequential Therapy in EGFR M+ NSCLC
MYEEE||Effectiveness of Dose Modification Strategies with Afatinib
MYEEE||Strategies in Managing EGFRM+ NSCLC
Malaysia Region Treatment stratergy with EGFR-TKIs Asian setting
Running the Marathon: Updated Evidence on Sequential EGFR TKI Approach in NSCLC (Q&A session)
Running the Marathon: Updated Evidence on Sequential EGFR TKI Approach in NSCLC (Presentation)
MYEEE||PeRsonalized apprOach in Lung adenocarciNoma with EGFR-TKI therapy (PROLONG)
Uncovering the Uncommon: Efficacy of Afatinib in Uncommon and Compound Mutations
Taking Cancer On Webinar – Let’s TOAST to Maximising Time on EGFR-TKI Therapy (Lecture)
Taking Cancer On Webinar – Let’s TOAST to Maximising Time on EGFR-TKI Therapy (Q&A)

Speaker

Dr_Cheah_Soon_Keat_Photo.jpg

Dr Cheah Soon Keat

Consultant Clinical Oncologist
Island Hospital Penang, Malaysia

RELATED CONTENT